Qlucore AB (publ) Market Cap ($326.04K)
Market Cap & Net Worth: Qlucore AB (publ) (NOVKAN)
Qlucore AB (publ) market cap. Qlucore AB (publ) (ST:NOVKAN) has a market capitalization of $326.04K (Skr3.03 Million) as of November 1, 2026. Listed on the ST stock exchange, this USA-based company holds position #31228 globally and #6342 in its home market, demonstrating a -54.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Qlucore AB (publ)'s stock price Skr0.03 by its total outstanding shares 121186228 (121.19 Million). Also see cash flow conversion of Qlucore AB (publ) for how efficiently the company converts equity into cash flow.
Qlucore AB (publ) Market Cap History (2025–2026)
Qlucore AB (publ) market cap history from 2025 to 2026. Data shows growth from $2.04 Million to $326.04K (0.00% CAGR). Check Qlucore AB (publ) (NOVKAN) stock price for real-time trading data and today's change.
Qlucore AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Qlucore AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Qlucore AB (publ) growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NOVKAN by Market Capitalization
Companies near Qlucore AB (publ) in the global market cap rankings as of November 1, 2026. Also see Qlucore AB (publ) total assets for a full breakdown of the balance sheet.
Key companies related to Qlucore AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Qlucore AB (publ) (2025–2026)
Market capitalization of Qlucore AB (publ) from 2025 to today. Between 2025 and today, Qlucore AB (publ)'s market cap moved from $2.04 Million to $ 326.04K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr326.04K | -84.02% |
| 2025 | Skr2.04 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Qlucore AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $326.04K USD |
| MoneyControl | $326.04K USD |
| MarketWatch | $326.04K USD |
| marketcap.company | $326.04K USD |
| Reuters | $326.04K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Qlucore AB (publ)
Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study… Read more